Please use this identifier to cite or link to this item:
Title: An open label follow-up study on amisulpride in the add-on treatment of bipolar I patients.
Author: Carta, Mauro Giovanni
Zairo, Fausta
Mellino, Gisa
Hardoy, Maria Carolina
Vieta i Pascual, Eduard, 1963-
Keywords: Trastorn bipolar
Manic-depressive illness
Issue Date: 2006
Publisher: BioMed Central
Abstract: Background: Atypical antipsychotics are widely used in the treatment of bipolar disorders.Amisulpride is an atypical antipsychotic that has been proven to be effective in treatment ofschizophrenia, major depressive disorder and, more recently, acute mania. At the moment,however, no study has assessed the effectiveness of this compound in maintenance therapy ofbipolar disorders. The purpose of this study was to assess the long-term effectiveness ofamisulpride in combination with standard treatments in patients with bipolar I disorder who haveshown inadequate responses to ongoing standard therapies.Methods: The study enrolled fourteen bipolar I outpatients, not responding to ongoing standard therapy.Three patients discontinued treatment but 11 were followed-up for 11.7 ± 8.2 months before(range 3-24 months) and 5.2 ± 2.7 months after the introduction of amisulpride (range 3-9months). Relapse rates before and during treatment with amisulpride were calculated inaccordance to an increase of 1 or more in Clinical Global Impressions Scale-Bipolar Version (CGI-BP) score that was accompanied by a change in therapy or to an exacerbation of the symptomsthat required hospitalization.Results: A statistically significant decrease in overall relapse rate was observed during the periodof amisulpride therapy compared with months previous to the introduction of amisulpride. Therelative risk of relapse in the absence of amisulpride therapy was 3.1 (χ2 = 4.2, P < 0.05). Similarly,the rates of manic/mixed and depressive relapse were decreased but only manic episodes reachedstatistical significance (RR = 5.3, χ2 = 5.2, P < 0.02).Discussion and conclusion: This open-label study suggests that long-term therapy withamisulpride may benefit patients by improving global symptoms of bipolar disorder and reducingthe rate of manic/mixed relapses. Large, randomized, double-blind, placebo-controlled studies areneeded to explore the benefits of adding long-term amisulpride to standard therapies for bipolardisorder.Published: 24 August 2006Clinical Practice and Epidemiology in Mental Health 2006, 2:19doi:10.1186/1745-0179-2-19Received: 18 April 2006Accepted: 24 August 2006This article is available from:© 2006 Carta et al; licensee BioMed Central Ltd.This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Note: Reproducció del document publicat a:
It is part of: Clinical practice and epidemiology in mental health : CP & EMH, 2006, vol. 2, p. 1-19
Related resource:
ISSN: 1745-0179
Appears in Collections:Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
573685.pdf214.8 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons